ExcisaninA, a diterpenoid compound purified from Isodon MacrocalyxinD, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway

Molecular Cancer Therapeutics

Volumn 8, Issue 4, 2009, Pages 873-882

  Deng, Rong ^a   Tang, Jun ^a   Xia, Liang Ping ^a   Li, Dan Dan ^a   Zhou, Wen Jun ^a   Wang, Lin Lin ^a   Feng, Gong Kan ^a   Zeng, Yi Xin ^a   Gao, You Heng ^b   Zhu, Xiao Feng ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DITERPENOID; DOXORUBICIN; EXCISANIN A; FLUORESCEIN ISOTHIOCYANATE; FLUOROURACIL; LIPOCORTIN 5; PROTEIN KINASE B; UNCLASSIFIED DRUG; 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE; ANTINEOPLASTIC AGENT; DITERPENE; HERBACEOUS AGENT; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL LINE; CELL NUCLEUS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG PURIFICATION; DRUG SENSITIZATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISODON; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DITERPENES; DRUGS, CHINESE HERBAL; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IN SITU NICK-END LABELING; ISODON; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66449116607     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1080     Document Type: Article

References (42)

1. Leung CH, Grill SP, Lam W, Han QB, Sun HD, Cheng YC. Novel mechanism of inhibition of nuclear factor-κ B DNA-binding activity by diterpenoids isolated from Isodon rubescens. Mol Pharmacol 2005;68:286-297
2. Wang L, Zhao WL, Yan JS, et al. Eriocalyxin B induces apoptosis of t(8; 21) leukemia cells through NF-κB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. Cell Death Differ 2007;14:306-317 (Pubitemid 46092233)
3. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991;254:274-277 (Pubitemid 21917339)
4. Tokunaga E, Oki E, Egashira A, et al. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008;8:27-36.
5. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-1274 (Pubitemid 46962095)
6. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005;94:29-86. (Pubitemid 41202364)
7. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053-2059 (Pubitemid 39534841)
8. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455-7464 (Pubitemid 41637985)
9. Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-573 (Pubitemid 40799249)
10. LoPiccolo J, Granville CA, Gills JJ, Dennis PA. Targeting Akt in cancer therapy. Anticancer Drugs 2007;18:861-874 (Pubitemid 47220704)
11. Crowell JA, Steele VE, Fay JR. Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 2007;6:2139-2148 (Pubitemid 47294742)
12. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
13. Fujita E, Fujita T, Ito N. [Studies on the constituents of the stems of Isodon trichocarpus Kudo]. Yakugaku Zasshi 1967;87:1150-1153
14. Sun HD, Huang SX, Han QB. Diterpenoids from Isodon species and their biological activities. Nat Prod Rep 2006;23:673-698 (Pubitemid 44455387)
15. Meade-Tollin LC, Wijeratne EM, Cooper D, et al. Ponicidin and oridonin are responsible for the antiangiogenic activity of Rabdosia rubescens, a constituent of the herbal supplement PC SPES. J Nat Prod 2004;67:2-4. (Pubitemid 38141300)
16. Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL, Wu JM. Differential control of growth, cell cycle progression, and expression of NF-κB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 2005;337:224-231 (Pubitemid 41393783)
17. Ikezoe T, Yang Y, Bandobashi K, et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-κB signal pathways. Mol Cancer Ther 2005;4:578-586 (Pubitemid 40601839)
18. Gao YH, Li GY, Yu KF, et al. Studies on the chemical constituents of Largesepal Rabdosia (Rabdosia Macrocalyx). Chin Tradit Herbal Drugs 1994;5:232-233
19. Hu ZY, Zhu XF, Zhong ZD, et al. ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. Int J Cancer 2008;123:2418-2429
20. Zhou JM, Zhu XF, Lu YJ, et al. Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines. Oncogene 2006;25:503-511 (Pubitemid 43164461)
21. Liu JN, Deng R, Guo JF, et al. Inhibition of myc promoter and telomerase activity and induction of delayed apoptosis by SYUIQ-5, a novel G-quadruplex interactive agent in leukemia cells. Leukemia 2007;21:1300-1302 (Pubitemid 46831820)
22. Zhu XF, Xie BF, Zhou JM, et al. Blockade of vascular endothelial growth factor receptor signal pathway and antitumor activity of ON-III (2′,4′-dihydroxy-6′-methoxy-3′,5′- dimethylchalcone), a component from Chinese herbal medicine. Mol Pharmacol 2005;67:1444-1450 (Pubitemid 40594143)
23. Zhang CH, Wen ZQ, Li JF, et al. Inhibition of proliferation and transforming growth factor β3 protein expression by peroxisome proliferators-activated receptor γ ligands in human uterine leiomyoma cells. Chin Med J (Engl) 2008;121:166-171
24. Hurst PR, Mora JM, Fenwick MA. Caspase-3, TUNEL and ultrastructural studies of small follicles in adult human ovarian biopsies. Hum Reprod 2006;21:1974-1980
25. Markaryan A, Nelson EG, Tretiakova M, Hinojosa R. Technical report: immunofluorescence and TUNEL staining of celloidin embedded human temporal bone tissues. Hear Res 2008;241:1-6.
26. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1:707-717
27. Siwak DR, Mendoza-Gamboa E, Tari AM. HER2/neu uses Akt to suppress retinoic acid response element binding activity in MDA-MB-453 breast cancer cells. Int J Oncol 2003;23:1739-1745
28. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 2008;68:6698-6707
29. Koizumi N, Hatano E, Nitta T, et al. Blocking of PI3K/Akt pathway enhances apoptosis induced by SN-38, an active form of CPT-11, in human hepatoma cells. Int J Oncol 2005;26:1301-1306
30. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-789 (Pubitemid 26004411)
31. Yang L, Dan HC, Sun M, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004;64:4394-4399 (Pubitemid 38856907)
32. Yu ZY, Liang YG, Xiao H, et al. Melissoidesin G, a diterpenoid purified from Isodon melissoides, induces leukemic-cell apoptosis through induction of redox imbalance and exhibits synergy with other anticancer agents. Int J Cancer 2007;121:2084-2094 (Pubitemid 47463174)
33. Gui MY, Aoyagi Y, Jin YR, Li XW, Hasuda T, Takeya K. Excisanin H, a novel cytotoxic 14,20-epoxy-ent-kaurene diterpenoid, and three new ent-kaurene diterpenoids from Rabdosia excisa. J Nat Prod 2004;67:373-376 (Pubitemid 38410616)
34. Aoyagi Y, Nishioka Y, Tobe F, et al. Synthesis of 1-O-monoacyl or 12-O-monoacyl, 1-,12-O-diacyl-, and 11,12-dehydrated excisanin A 7,14-acetonides and their cytotoxic activity. Bioorg Med Chem 2006;14:5802-5811 (Pubitemid 44080594)
35. Deng R, Li W, Guan Z, et al. Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis. Oncogene 2006;25:7070-7077 (Pubitemid 44722074)
36. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-262 (Pubitemid 37329790)
37. Chen YL, Law PY, Loh HH. Inhibition of akt/protein kinase B signaling by naltrindole in small cell lung cancer cells. Cancer Res 2004;64:8723-8730 (Pubitemid 39552089)
38. Mandal M, Kim S, Younes MN, et al. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 2005;92:1899-1905 (Pubitemid 40826139)
39. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2:1093-1103
40. Kumar CC, Madison V. AKT crystal structure and AKT-specific inhibitors. Oncogene 2005;24:7493-7501 (Pubitemid 41637989)
41. Rhodes N, Heerding DA, Duckett DR, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 2008;68:2366-2374
42. Chee KG, Longmate J, Quinn DI, et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 2007;5:433-437